Proteomics of gliomas: Initial biomarker discovery and evolution of technology

Neuro-Oncology

Volumn 13, Issue 9, 2011, Pages 926-942

  Kalinina, Juliya ^a   Peng, Junmin ^b   Ritchie, James C ^b   Van Meir, Erwin G ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Glioma; Proteomics

Indexed keywords

ALPHA ENOLASE; ATTRACTIN; BETA ACTIN; CARBONATE DEHYDRATASE; CASPASE 14; CATHEPSIN D; CATHEPSIN L; CD74 ANTIGEN; CREATINE KINASE BB; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYSTATIN B; ENOLASE; FIBROBLAST GROWTH FACTOR 14; FIBROBLAST GROWTH FACTOR 4; GALECTIN 1; GALECTIN 3; GELSOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HEAT SHOCK PROTEIN 70; KI 67 ANTIGEN; LIPOCORTIN 1; NUCLEOSIDE DIPHOSPHATE KINASE A; PROTEIN DISULFIDE ISOMERASE; PROTEIN P53; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STATHMIN; TENASCIN; UBIQUITIN; UNINDEXED DRUG; VIMENTIN;

ANTIGEN BINDING; ASTROCYTOMA; BETA CHAIN; BODY FLUID; BOTTLENECK POPULATION; BRAIN CANCER; BRAIN TUMOR; CANCER TISSUE; CEREBROSPINAL FLUID ANALYSIS; DISEASE MARKER; FOLLOW UP; FRAGMENTATION REACTION; GEL ELECTROPHORESIS; GENOMICS; GLIOMA; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; LIQUID CHROMATOGRAPHY; METABOLOMICS; MOLECULAR IMAGING; MOLECULAR WEIGHT; PHAGOCYTOSIS; PLASMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SERUM; TISSUE MICROARRAY; TUMOR BIOPSY;

BRAIN NEOPLASMS; GLIOMA; HUMANS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052746574     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor078     Document Type: Review

References (114)

1. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60(3):166-193.
2. Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir EG. Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol. 2002;9(1):24-36.
3. Louis DN. WHO classification of tumours of the central nervous system. 4th ed. Lyon: 2007.
4. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol. 2010;120(5):567-584.
5. Tohma Y, Gratas C, Van Meir EG, et al. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol. 1998;57(3):239-245. (Pubitemid 28125504)
6. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002;1(9):683-695. (Pubitemid 37361543)
7. Cravatt BF, Simon GM, Yates JR, III. The biological impact of mass-spectrometry-based proteomics. Nature. 2007;450(7172): 991-1000. (Pubitemid 350273629)
8. Gstaiger M, Aebersold R. Applying mass spectrometry-based proteomics to genetics, genomics and network biology. Nat Rev Genet. 2009;10(9):617-627.
9. Choudhary C, Mann M. Decoding signalling networks by mass spectrometry-based proteomics. Nat Rev Mol Cell Biol. 2010;11(6):427-439.
10. Niclou SP, Fack F, Rajcevic U. Glioma proteomics: status and perspectives. J Proteomics. 2010;73(10):1823-1838.
11. Khwaja FW, Van Meir EG. Proteomic discovery of biomarkers in the cerebrospinal fluid of brain tumor patients. In: Van Meir, ed. CNS cancer: Models, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009: 577-614.
12. D'Aguanno S, Del Boccio P, Bernardini S, et al. Electrophoretic separations of cerebrospinal fluid proteins in clinical investigations. Clin Chem Lab Med. 2007;45(4):437-449. (Pubitemid 46632226)
13. Kennedy S. Proteomic profiling from human samples: the body fluid alternative. Toxicol Lett. 2001;120(1-3):379-384. (Pubitemid 32375105)
14. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z. Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B. 2005;6(1): 4-10.
15. Zhang H, Wu G, Tu H, Huang F. Discovery of serum biomarkers in astrocytoma by SELDI-TOF MS and proteinchip technology. J Neurooncol. 2007;84(3):315-323. (Pubitemid 47108522)
16. Petrik V, Saadoun S, Loosemore A, et al. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem. 2008;54(4):713-722. (Pubitemid 351573704)
17. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470-1476.
18. Abbott NJ. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol. 2005;25(1):5-23. (Pubitemid 40558582)
19. Righetti PG, Castagna A, Antonucci F, et al. Proteome analysis in the clinical chemistry laboratory: myth or reality? Clin Chim Acta. 2005;357(2):123-139. (Pubitemid 40894637)
20. Fountoulakis M, Kossida S. Proteomics-driven progress in neurodegeneration research. Electrophoresis. 2006;27(8): 1556-1573.
21. Zougman A, Pilch B, Podtelejnikov A, et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res. 2008;7(1):386-399. (Pubitemid 351171153)
22. Khwaja FW, Duke-Cohan JS, Brat DJ, Van Meir EG. Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration. Clin Cancer Res. 2006;12(21): 6331-6336. (Pubitemid 44799701)
23. Khwaja FW, Nolen JD, Mendrinos SE, et al. Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics. 2006;6(23):6277-6287. (Pubitemid 44935514)
24. Khwaja FW, Reed MS, Olson JJ, et al. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res. 2007;6(2):559-570. (Pubitemid 46340160)
25. Schuhmann MU, Zucht HD, Nassimi R, et al. Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur J Surg Oncol. 2009;36(2):201-207.
26. Zheng PP, Luider TM, Pieters R, et al. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol. 2003;62(8):855-862. (Pubitemid 37082779)
27. Ohnishi M, Matsumoto T, Nagashio R, et al. Proteomics of tumorspecific proteins in cerebrospinal fluid of patients with astrocytoma: usefulness of gelsolin protein. Pathol Int. 2009;59(11):797-803.
28. Schutzer SE, Liu T, Natelson BH, et al. Establishing the proteome of normal human cerebrospinal fluid. PLoS One. 2010;5(6):e10980.
29. Iwadate Y, Sakaida T, Hiwasa T, et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res. 2004;64(7):2496-2501. (Pubitemid 38523905)
30. Furuta M, Weil RJ, Vortmeyer AO, et al. Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene. 2004;23(40):6806-6814. (Pubitemid 39280012)
31. Schwartz SA, Weil RJ, Johnson MD, Toms SA, Caprioli RM. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin Cancer Res. 2004;10(3):981-987. (Pubitemid 38198899)
32. Li J, Yin C, Okamoto H, et al. Identification of a novel proliferationrelated protein, WHSC1 4a, in human gliomas. Neuro Oncol. 2008;10(1):45-51. (Pubitemid 351250899)
33. Mustafa DA, Burgers PC, Dekker LJ, et al. Identification of glioma neovascularization-related proteins by using MALDI-FTMS and nano-LC fractionation to microdissected tumor vessels. Mol Cell Proteomics. 2007;6(7):1147-1157. (Pubitemid 47099226)
34. Khalil AA. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. 2007;98(2):201-213. (Pubitemid 44941872)
35. Li J, Zhuang Z, Okamoto H, et al. Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers. Neurology. 2006;66(5):733-736. (Pubitemid 43739831)
36. Jiang R, Mircean C, Shmulevich I, et al. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics. 2006;6(10):2964-2971. (Pubitemid 43806395)
37. Schwartz SA, Weil RJ, Thompson RC, et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res. 2005;65(17):7674-7681. (Pubitemid 41297241)
38. Odreman F, Vindigni M, Gonzales ML, et al. Proteomic studies on lowand high-grade human brain astrocytomas. J Proteome Res. 2005;4(3):698-708. (Pubitemid 40863258)
39. Wang Y, Rudnick PA, Evans EL, et al. Proteome analysis of microdissected tumor tissue using a capillary isoelectric focusing-based multidimensional separation platform coupled with ESI-tandem MS. Anal Chem. 2005;77(20):6549- 6556. (Pubitemid 41504436)
40. Iwadate Y, Sakaida T, Saegusa T, et al. Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas. Int J Oncol. 2005;26(4): 993-998.
41. Chumbalkar VC, Subhashini C, Dhople VM, et al. Differential protein expression in human gliomas and molecular insights. Proteomics. 2005;5(4):1167-1177. (Pubitemid 40469044)
42. Park CK, Jung JH, Park SH, Jung HW, Cho BK. Multifarious proteomic signatures and regional heterogeneity in glioblastomas. J Neurooncol. 2009;94(1):31-39.
43. Melchior K, Tholey A, Heisel S, et al. Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches. J Proteome Res. 2009;8(10):4604-4614.
44. An JH, Lee SY, Jeon JY, Cho KG, Kim SU, Lee MA. Identification of gliotropic factors that induce human stem cell migration to malignant tumor. J Proteome Res. 2009;8(6):2873-2881.
45. Koncarevic S, Urig S, Steiner K, et al. Differential genomic and proteomic profiling of glioblastoma cells exposed to terpyridineplatinum(II) complexes. Free Radic Biol Med. 2009;46(8):1096-1108.
46. Hill JJ, Moreno MJ, Lam JC, Haqqani AS, Kelly JF. Identification of secreted proteins regulated by cAMP in glioblastoma cells using glycopeptide capture and label-free quantification. Proteomics. 2009;9(3):535-549.
47. Bian XW, Xu JP, Ping YF, et al. Unique proteomic features induced by a potential antiglioma agent, Nordy (dl-nordihydroguaiaretic acid), in glioma cells. Proteomics. 2008;8(3):484-494.
48. Seyfried NT, Huysentruyt LC, Atwood JA, III, Xia Q, Seyfried TN, Orlando R. Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: a membrane proteomics approach. Cancer Lett. 2008;263(2):243-252.
49. Puchades M, Nilsson CL, Emmett MR, et al. Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. J Proteome Res. 2007;6(2):869-875. (Pubitemid 46340191)
50. Ngo TT, Peng T, Liang XJ, et al. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst. 2007;99(8):639-652. (Pubitemid 47073545)
51. Shim JH, Kim YS, Bahk YY. Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN-expressing U-87 MG human glioblastoma cells. Proteomics. 2006;6(1):81-93. (Pubitemid 43142936)
52. Trog D, Fountoulakis M, Friedlein A, Golubnitschaja O. Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions. Proteomics. 2006;6(9):2924-2930.
53. Zhou L, Wang Y, Zhang YT, Geng YP, Si LS, Wang YL. Proteomics-based analysis of a pair of glioma cell lines with different tumor forming characteristics. Neurosci Lett. 2006;401(1-2):59-64.
54. Billecke C, Malik I, Movsisyan A, et al. Analysis of glioma cell platinum response by metacomparison of two-dimensional chromatographic proteome profiles. Mol Cell Proteomics. 2006;5(1):35-42. (Pubitemid 43169338)
55. Vogel TW, Zhuang Z, Li J, et al. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res. 2005;11(10):3624-3632. (Pubitemid 40685577)
56. Khwaja FW, Svoboda P, Reed M, Pohl J, Pyrzynska B, Van Meir EG. Proteomic identification of the wt-p53-regulated tumor cell secretome. Oncogene. 2006;25(58):7650-7661. (Pubitemid 44924478)
57. Rajcevic U, Petersen K, Knol JC, et al. iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics. 2009;8(11):2595-2612.
58. Goplen D, Wang J, Enger PO, et al. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res. 2006;66(20):9895-9902. (Pubitemid 44672041)
59. Wibom C, Pettersson F, Sjostrom M, Henriksson R, Johansson M, Bergenheim AT. Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment. Br J Cancer. 2006;94(12):1853-1863. (Pubitemid 43882576)
60. Hunt SM, Thomas MR, Sebastian LT, et al. Optimal replication and the importance of experimental design for gel-based quantitative proteomics. J Proteome Res. 2005;4(3):809-819. (Pubitemid 40863269)
61. Hale JE, Gelfanova V, You JS, Knierman MD, Dean RA. Proteomics of cerebrospinal fluid: methods for sample processing. Methods Mol Biol. 2008;425:53-66.
62. Shi M, Caudle WM, Zhang J. Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol Dis. 2009;35(2):157-164.
63. Yuan X, Desiderio DM. Human cerebrospinal fluid peptidomics. J Mass Spectrom. 2005;40(2):176-181. (Pubitemid 40327257)
64. Carrette O, Burkhard PR, Sanchez JC, Hochstrasser DF. State-of-the-art two-dimensional gel electrophoresis: a key tool of proteomics research. Nat Protoc. 2006;1(2):812-823.
65. Davidsson P, Paulson L, Hesse C, Blennow K, Nilsson CL. Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. Proteomics. 2001;1(3):444-452. (Pubitemid 33585117)
66. Zheng PP, Kros JM, Sillevis-Smitt PA, Luider TM. Proteomics in primary brain tumors. Front Biosci. 2003;8:d451-d463. (Pubitemid 38943203)
67. Rajcevic U, Niclou SP, Jimenez CR. Proteomics strategies for target identification and biomarker discovery in cancer. Front Biosci. 2009;14:3292-3303.
68. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem. 2005;382(3):669-678. (Pubitemid 40890994)
69. Gallo P, Bracco F, Morara S, Battistin L, Tavolato B. The cerebrospinal fluid transferrin/tau proteins. A study by two-dimensional polyacrylamide gel electrophoresis (2D) and agarose isoelectrofocusing (IEF) followed by double-antibody peroxidase labeling and avidin-biotin amplification. J Neurol Sci. 1985;70(1):81-92. (Pubitemid 15019902)
70. Wiederkehr F, Vonderschmitt DJ. [2-dimensional electrophoresis of cerebrospinal fluid in various neurological patients]. Schweiz Med Wochenschr. 1985;115(11):368-373. (Pubitemid 15140182)
71. Chaurand P, Schwartz SA, Reyzer ML, Caprioli RM. Imaging mass spectrometry: principles and potentials. Toxicol Pathol. 2005;33(1):92-101. (Pubitemid 40216808)
72. Sadygov RG, Cociorva D, Yates JR, III. Large-scale database searching using tandem mass spectra: looking up the answer in the back of the book. Nat Methods. 2004;1(3):195-202.
73. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol. 2006;7(12):952-958. (Pubitemid 44871421)
74. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science. 2006;312(5771):212-217.
75. Washburn MP, Wolters D, Yates JR, III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol. 2001;19(3):242-247. (Pubitemid 32220565)
76. Peng J, Elias JE, Thoreen CC, Licklider LJ, Gygi SP. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J Proteome Res. 2003;2(1):43-50. (Pubitemid 36207189)
77. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422(6928):198-207. (Pubitemid 36362757)
78. Liu H, Sadygov RG, Yates JR, III. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem. 2004;76(14):4193-4201. (Pubitemid 38943698)
79. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999;17(10):994-999. (Pubitemid 29474856)
80. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 2004;3(12):1154-1169.
81. Zhu H, Pan S, Gu S, Bradbury EM, Chen X. Amino acid residue specific stable isotope labeling for quantitative proteomics. Rapid Commun Mass Spectrom. 2002;16(22):2115-2123. (Pubitemid 35340078)
82. Kruger M, Moser M, Ussar S, et al. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell. 2008;134(2):353-364. (Pubitemid 352010327)
83. Liu P, Hwang JT. Quick calculation for sample size while controlling false discovery rate with application to microarray analysis. Bioinformatics. 2007;23(6):739-746. (Pubitemid 46554726)
84. Hamacher M, Apweiler R, Arnold G, et al. HUPO Brain Proteome Project: summary of the pilot phase and introduction of a comprehensive data reprocessing strategy. Proteomics. 2006;6(18): 4890-4898. (Pubitemid 44483886)
85. Gannot G, Tangrea MA, Erickson HS, et al. Layered peptide array for multiplex immunohistochemistry. J Mol Diagn. 2007;9(3):297-304. (Pubitemid 47305065)
86. Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol. 2001;195(1):72-79.
87. Wang H, Zhang W, Fuller GN. Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain Pathol. 2002;12(1):95-107. (Pubitemid 33131366)
88. Ikota H, Kinjo S, Yokoo H, Nakazato Y. Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol. 2006;111(5):475-482.
89. Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009;27(7):633-641.
90. Cheng D, Hoogenraad CC, Rush J, et al. Relative and absolute quantification of postsynaptic density proteome isolated from rat forebrain and cerebellum. Mol Cell Proteomics. 2006;5(6):1158-1170. (Pubitemid 43985938)
91. Griffin JL, Kauppinen RA. A metabolomics perspective of human brain tumours. FEBS J. 2007;274(5):1132-1139.
92. Mao H, Toufexis D, Wang X, Lacreuse A, Wu S. Changes of metabolite profile in kainic acid induced hippocampal injury in rats measured by HRMAS NMR. Exp Brain Res. 2007;183(4):477-485. (Pubitemid 350029364)
93. Kamleh MA, Dow JA, Watson DG. Applications of mass spectrometry in metabolomic studies of animal model and invertebrate systems. Brief Funct Genomic Proteomic. 2009;8(1):28-48.
94. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res. 2009;15(2):431-440.
95. Tao F. 1st NCI annual meeting on Clinical Proteomic Technologies for Cancer. Expert Rev Proteomics. 2008;5(1):17-20. (Pubitemid 351287737)
96. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
97. Hanash SM, Bobek MP, Rickman DS, et al. Integrating cancer genomics and proteomics in the post-genome era. Proteomics. 2002;2(1):69-75. (Pubitemid 34273100)
98. Zhang R, Tremblay TL, McDermid A, Thibault P, Stanimirovic D. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia. 2003;42(2):194-208. (Pubitemid 36565123)
99. Hiratsuka M, Inoue T, Toda T, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun. 2003;309(3):558-566. (Pubitemid 37083288)
100. Hobbs SK, Shi G, Homer R, Harsh G, Atlas SW, Bednarski MD. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging. 2003;18(5):530-536. (Pubitemid 37339797)
101. Fiore G, Di Cristo C, Monti G, et al. Tubulin nitration in human gliomas. Neurosci Lett. 2006;394(1):57-62. (Pubitemid 43052974)
102. Bouamrani A, Ternier J, Ratel D, et al. Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics. Clin Chem. 2006;52(11):2103-2106. (Pubitemid 44658214)
103. Okamoto H, Li J, Glasker S, et al. Proteomic comparison of oligodendrogliomas with and without 1pLOH. Cancer Biol Ther. 2007;6(3):391-396. (Pubitemid 47328307)
104. Guo T, Wang W, Rudnick PA, et al. Proteome analysis of microdissected formalin-fixed and paraffin-embedded tissue specimens. J Histochem Cytochem. 2007;55(7):763-772. (Pubitemid 46981773)
105. Park CK, Kim JH, Moon MJ, et al. Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression. J Cancer Res Clin Oncol. 2008;134(2):255-262. (Pubitemid 350234071)
106. Fischer Jde S, Carvalho PC, Neves-Ferreira AG, et al. Anti-thrombin as a prognostic biomarker candidate for patients with recurrent glioblastoma multiform under treatment with perillyl alcohol. J Exp Ther Oncol. 2008;7(4):285-290.
107. Zhang M, Wan C, Ji B, et al. Proteome alteration of U251 human astrocytoma cell after inhibiting retinoic acid synthesis. Mol Cell Biochem. 2009;323(1-2):185-193.
108. Park CK, Jung JH, Moon MJ, et al. Tissue expression of manganese superoxide dismutase is a candidate prognostic marker for glioblastoma. Oncology. 2009;77(3-4):178-181.
109. Grzendowski M, Riemenschneider MJ, Hawranke E, et al. Simultaneous extraction of nucleic acids and proteins from tissue specimens by ultracentrifugation: A protocol using the high-salt protein fraction for quantitative proteome analysis. Proteomics. 2009;9(21): 4985-4990.
110. Fischer Jde S, Liao L, Carvalho PC, et al. Dynamic proteomic overview of glioblastoma cells (A172) exposed to perillyl alcohol. J Proteomics. 2010;73(5):1018-1027.
111. Grzendowski M, Wolter M, Riemenschneider MJ, et al. Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q. Neuro Oncol. 2010;12(3): 243-256.
112. Rostomily RC, Born DE, Beyer RP, et al. Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion. J Proteome Res. 2010;9(5):2610-2618.
113. Geiger T, Cox J, Ostasiewicz P, Wisniewski JR, Mann M. Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat Methods. 2010;7(5):383-385.
114. Fischer JS, Carvalho P, da Fonseca CO, et al. Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol. J Proteome Res. 2011;10(1):153-160.